"Wherever there are people, there is a jianghu (a world of martial arts and chivalry)." This is a line from the movie *Ash Is Purest White*. The jianghu here refers to the environment deep within each of us. In our respective environments, everyone dreams of soaring to great heights and achieving their aspirations, but most must experience setbacks before truly understanding their inner selves and gaining a deeper understanding of themselves.

"Once you enter the jianghu, time flies." The pharmaceutical machinery industry is also a jianghu. In this jianghu, there is competition and cooperation; there is commerce and public welfare; there is tradition and innovation… Every pharmaceutical machinery company is striving to achieve greater and higher goals. Currently, my country has over a thousand professional pharmaceutical machinery companies and manufacturers, with sales continuously rising. Among these thousand-plus pharmaceutical machinery companies, besides some backbone enterprises and some with medium to high strength, most companies are not particularly strong. Furthermore, with the end of GMP certification, the market has begun to cool down, and pharmaceutical machinery companies have reached a watershed moment. Industry experts say that in the post-GMP era, most pharmaceutical machinery companies will face both the vicious competition of the downturn and the bitter consequences of their rapid expansion during the peak period. It is understood that after the market shrinks, price reduction has become a competitive tactic for many pharmaceutical machinery companies, including leading enterprises. Two leading companies with highly overlapping products once engaged in fierce market competition to seize the top market share, their "battle" even extending to the Indian market. However, this competition yielded no significant results; instead, both companies' profits were less than ideal. In the pharmaceutical machinery industry, price reduction is neither the only nor the most effective means to cope with market competition. To gain a foothold in this competitive market, pharmaceutical machinery companies need to address challenges in ways that align with industry trends and market demands. Industry insiders suggest that in the current environment of strict market regulation and continuously improving industry innovation, companies should prioritize research and development. After all, forming core value is crucial for pharmaceutical machinery companies to succeed in the market. Furthermore, relevant departments should introduce and strengthen policies for technology protection. "Inadequate technology protection is one of the important reasons for the low enthusiasm of developers. Once a new model is launched, a batch of imitations appears very quickly, and a new round of price competition will begin again," a pharmaceutical machinery company stated. They added that serious equipment copying affects the overall technological level, preventing the industry from achieving new breakthroughs. As competition intensifies further in the domestic pharmaceutical machinery industry, product homogenization and technological backwardness will become increasingly prominent. Furthermore, foreign companies are also making further plans for the Chinese market. Faced with internal and external challenges, how should Chinese pharmaceutical machinery companies survive in this competitive landscape? First, these companies must conduct self-diagnosis, recognizing their own problems in order to improve both internally and externally after the initial pain. Second, they must take concrete actions and implement effective measures, not just relying on price reductions, but on innovation to overcome difficulties. Finally, in this competitive market, pharmaceutical machinery companies must not forget their roots, nor be blinded by profits; honest operation, quality production, and innovative development are the true keys to success.